Patient information regarding subcutaneous self-administration of sumatriptan (imitrex).
نویسنده
چکیده
Written instructions and accompanying photographs dealing with self-administration of sumatriptan are available at most pharmacies and are enclosed in the self-dosing kit you will receive with your initial prescription. While preparation of the auto-injector is not particularly difficult, it is a good idea to familiarize yourself with its use during a quiet time when you are free of headache or other distractions. You may load the auto-injector at your leisure and thus have the auto-injector ready to use when you need it for severe headache. You should not take sumatriptan if you have a history of heart disease, poorly controlled high blood pressure, or severe blood vessel spasm of any type. You should not use sumatriptan if you are experiencing chest pain along with an acute headache. If you are uncertain as to whether it is safe for you to use sumatriptan, consult your doctor. Sumatriptan should not be administered within 24 hours of your taking an ergotamine preparation (examples include Cafergot, Ergocaff PB, dihydroergotamine/DHE), and you must wait at least 6 hours after administering sumatriptan before taking any ergotamine preparation. Taking sumatriptan and an ergotamine simultaneously or too close together may result in blood vessel spasm and, potentially, angina, heart attack, or stroke. Sumatriptan should be used cautiously in individuals also taking an MAO inhibitor (eg, Nardil). Common side effects of sumatriptan include nausea, temporary increase in headache, facial flushing or tingling, short-lived pain at the injection site, and a temporary sensation of muscle “tightening,” which most often involves the neck or chest. Less common potential side effects include a “burning” or “scalding” sensation involving the skin, and allergic reactions (extending from rash to anaphylactic “shock”). There are reports, albeit very rare, of true angina, heart attack, heart arrhythmia, or stroke as possible complications of sumatriptan use. Used as indicated, however, all data indicate that injectable sumatriptan is exceedingly safe. Administering a second injection of sumatriptan following initial injection is unlikely to help your headache if the initial injection was ineffective. On the other hand, many patients experience recurrent headache within 24 hours following successful treatment of their headaches with the initial sumatriptan injection, and, if such is your experience, you may give yourself a second injection to treat this recurrent headache. The recommended maximum total number of injections per 24-hour period is 2. To maximize your therapeutic response to injectable sumatriptan and minimize side effects, administer the medication as soon as your headache reaches the level of moderate or severe intensity.
منابع مشابه
Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs
BACKGROUND Several sumatriptan subcutaneous autoinjector devices for acute treatment of migraine patients are available, each device differs with respect to design and features. Determining device preference and ease of use is important because patients experiencing a migraine attack are often functionally impaired. OBJECTIVE The objective of this human factors study was to compare migraine p...
متن کاملThe effect of weight, body mass index, age, sex, and race on plasma concentrations of subcutaneous sumatriptan: a pooled analysis
OBJECTIVE/BACKGROUND Factors such as body size (weight and body mass index [BMI]), age, sex, and race might influence the clinical response to sumatriptan. We evaluated the impact of these covariates on the plasma concentration (Cp) profile of sumatriptan administered subcutaneously. METHODS We conducted three pharmacokinetic studies of subcutaneous sumatriptan in 98 healthy adults. Sumatript...
متن کاملImitrex Tablets Formulated with Rt Technologytm
succinate) was the first triptan medication to target the nerves and blood vessels believed to trigger a total migraine (including throbbing pain, nausea, and sensitivity to light and sound, with or without aura). The first triptan to receive Food and Drug Administration (FDA) approval for the acute treatment of migraines in adults, IMITREX has treated more than 750 million migraines in the pas...
متن کاملComparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial
Background: Sodium valproate (SV) has been approved for migraine prophylaxis and its intravenous form is used to treat acute migraine attacks. We compared the efficacy and safety of intravenous SV and subcutaneous Sumatriptan in managing acute migraine attacks. Methods: This double-blind randomized clinical trial divided 90 patients into two groups: one group received 400 mg of intravenous SV a...
متن کاملSubcutaneous delivery of sumatriptan in the treatment of migraine and primary headache
Subcutaneous sumatriptan is an effective treatment for pain from acute migraine headache, and can be used in patients with known migraine syndrome and in patients with primary headaches when secondary causes have been excluded. In limited comparative trials, subcutaneous sumatriptan performed in a manner comparable with oral eletriptan and intravenous metoclopramide, was superior to intravenous...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Headache
دوره 47 4 شماره
صفحات -
تاریخ انتشار 2007